


PHARMACEUTICAL 2021



REGENERON PHARMACEUTICALS INC. Rank 8 of 409







PHARMACEUTICAL 2021



REGENERON PHARMACEUTICALS INC.



Rank 8 of 409

The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 390% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 7.1% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 581% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	9,779,100
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,697,400
Liabilities, Non-Current	1,978,500
Other Assets	7,384,200
Other Compr. Net Income	8,200
Other Expenses	1,136,700
Other Liabilities	1,462,100
Other Net Income	233,800
Property and Equipment	0
Research and Development	2,735,000
Revenues	8,497,100
Selling, General and Administrative Expense	1,346,000

Output Variable	Value in 1000 USD
Assets	17,163,300
Liabilities	6,138,000
Expenses	5,217,700
Stockholders Equity	11,025,300
Net Income	3,513,200
Comprehensive Net Income	3,517,300
Economic Capital Ratio	227%